Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

While Washington Stews, You Can Cash In on the Biggest "Tax-Inversion" Deal in History

Back in June 2012, we recommended that you pick up shares of Big Pharma player Abbott Laboratories Inc. (NYSE: ABT). The reason: Abbott was planning to split in two at the end of the year, meaning folks who took our advice would end up with stakes in two companies for the price of one.

There was more than bargain-basement thinking at work here.

You see, these corporate breakups – known as spin-offs – have a habit of turning into market-beating profit plays. And the newly minted spin-off firms often end up as takeover fodder – also at big profits.

Abbott followed part of that blueprint.

  • Featured Story

    How to Trade Weekly Options

    To loosely paraphrase Robert Burns, the best-laid plans of mice and stock traders sometimes go awry.

    But with some creative use of weekly options, that doesn't necessarily mean you have to take your losses.

    Here's an example of what I mean.

    Just under two weeks ago, we suggested a "short iron condor" as a possible short-term strategy for playing the release of first-quarter earnings reports for some of the leading financial stocks, using J.P. Morgan Chase (NYSE: JPM) as a specific example.

    As it turned out, JPM's earnings handily topped the estimates - coming in at $1.31 per share versus a projected $1.14, on revenues of $26.7 billion ($24.4 billion had been predicted).

    That should have sent the stock nicely higher, giving us a quick gain on our condor - and JPM did indeed try to rally - but then our best-laid plans took a wrong turn.

    The broad market turned sharply lower that Friday, with the Dow Jones Industrials dropping 136.99 points and the S&P 500 losing 17.31, dragging J.P. Morgan along with it.

    Long story short, over the next five days JPM see-sawed higher and lower - but save for a few moments on Thursday, it never moved out of our $43-$45 maximum-loss range. The trade went south.

    But had you been on your toes, you would have noticed this about JPM: In spite of the pressure from a weak overall market, the stock demonstrated strong technical support at the $43-a-share level. Both times it tested $43, it bounced quickly back - a pattern it repeated Monday, when it ignored the broad market sell-off and rapidly rebounded from a lower gap opening near $42.

    The rest of this week, it's again traded solidly above $43 a share. In fact, a quick look at the long-term chart shows that - with the exception of Monday - JPM hasn't closed below $43 since March 12th. And, given the healthy earnings and a "powerful buy" rating last Thursday from Zacks Investment Research, it probably won't close below that level again.

    At least not in the next week or two...

    To continue reading, please click here...
    Read More...
  • buy weekly options